-
Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review
In January 2024, a study led by Professor Ting Niu from West China Hospital, Sichuan University was published in the international academic journal ——Frontiers In Oncology. The title of the…
-
Ectopic expression of transcription factor ONECUT3 drives complex karyotype in Myelodysplastic Syndromes
In February 2024, a study led by Professor Hongyan Tong from the First Affiliated Hospital, Zhejiang University School of Medicine was published in the international academic journal ——Journal of Clinical…
-
Consolidation Therapy for Acute Myeloid Leukemia in Older Patients: A Study on the Efficacy of Decitabine and Intermediate-Dose Cytarabine
Consolidation Therapy for Acute Myeloid Leukemia in Older Patients: A Study on the Efficacy of Decitabine and Intermediate-Dose Cytarabine
-
Annual Review | Professor Hui Wei: Progress in Clinical Diagnosis and Treatment of Acute Myeloid Leukemia (AML)
With ardent vigor and unwavering dedication, the past year has seen significant advances in the field of hematologic oncology, driven by the rapid development of innovative therapies and cutting-edge technologies. The application of novel molecular biology techniques has not only refined the prognostic stratification of Acute Myeloid Leukemia (AML) but has also fostered more precise…
-
Professor LanPing Xu: Hematopoietic Stem Cell Transplantation for the Treatment of Severe Aplastic Anemia | 2024 CSCO Hematology Academic Conference
From January 26 to 28, 2024, the “Chinese Society of Clinical Oncology (CSCO) Leukemia Committee, Lymphoma Committee, and Myeloma Preparatory Committee Work Meeting and 2024 CSCO Blood, Lymphoma, and Myeloma Diseases Academic Conference” was held in Haikou. Many authoritative hematologists from home and abroad gathered to share their insights. Professor LanPing Xu from the Hematology…
-
Professor Huilai Zhang : Diligently Striving to Improve Survival Time and Quality of Life for Lymphoma Patients in China | 2024 CSCO Hematology
Lymphoma is one of the fastest-growing malignant tumors worldwide, and the incidence rate in China has been gradually increasing in recent years, posing a serious threat to the health of the population. From January 26 to 28, 2024, the “Work Conference of the Leukemia Committee, Lymphoma Committee, and Myeloma Preparatory Committee of the Chinese Society…
-
Professor Shuye Wang: Emphasizing early diagnosis and treatment of systemic amyloidosis to improve patient cure rates | 2024 CSCO Hematology Academic
Due to its low incidence and diverse clinical manifestations, patients with AL amyloidosis are often misdiagnosed or underdiagnosed, resulting in insufficient treatment. From January 26th to 28th, 2024, the “China Society of Clinical Oncology (CSCO) Leukemia Expert Committee, Lymphoma Expert Committee, and Myeloma Preparatory Committee Working Meeting, and the 2024 CSCO Hematology, Lymphoma, and Myeloma…
-
Professor Yang Liang:Research Progress and Reflections on BTK Inhibitors in the Treatment of CLL Patients | 2024 CSCO Hematology Academic Conference
In recent years, with the emergence of new targeted drugs such as ibrutinib and zanubrutinib, the treatment strategies for chronic lymphocytic leukemia (CLL) patients have been changing, sparking widespread discussions. At the recent 2024 CSCO Hematology Academic Conference, Professor Yang Liang from Sun Yat-sen University Cancer Center shared some thoughts on the classical international phase…
Connecting Medical Expertise through Media